“Preventive Medicine” has arrived for those at risk for HIV. New medical strategies are available to help prevent HIV from being transmitted. As futuristic as this concept seems, it is part of a preventive revolution for medical care – where an “ounce of prevention” may be worth more than a “pound of cure.”
Raphael Landovitz’s clinical research career focuses on optimizing the use of HIV antiretroviral therapy for both HIV treatment and HIV prevention.
Dr. Landovitz was trained at Princeton University and Harvard Medical School. He completed post-graduate training in internal medicine at Brigham and Women’s Hospital (1996-1999) and Infectious Diseases and HIV Medicine at Brigham and Women’s Hospital and Massachusetts General Hospital (1999-2001). He works in the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the NICHD-funded Adolescent Trials Network (ATN), and serves as the Clinical Research Site leader of the UCLA CARE Center Clinical Research Site for the DAIDS-funded networks. He is the principal investigator of a multisite PrEP demonstration project in Los Angeles County, and the protocol chair of Phase 2a and Phase 2b/3 studies of long-acting injectable PrEP using GSK1265744 (cabotegravir).